Asset profile
FB825
Monoclonal antibody
Evidence outlook · lead readout
NCT05059509 · Atopic Dermatitis
The reported results come from study designs that frequently fail to replicate under controlled conditions — see the rationale below.
NCT05059509: This was an open-label study with no control group and no blinding, so any change seen cannot be reliably attributed to the drug rather than natural variation; results have not been posted.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (1)
May 2027 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchAll registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.